to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers

Inclusion criteria

• Male volunteers in the age between 20 and 55 years old
• Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data
• Body Mass Index (BMI) in the range of 18.5 to 27 kg/m2
• Available for the entire study period
• Willing to adhere to protocol requirements and sign a informed consent form

Exclusion criteria

• History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, cardiovascular disease
• Clinically significant vital sign

• SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 140 mmHg
• DBP(Diastolic Blood Pressure) ≤ 60 mmHg or DBP ≥ 100 mmHg
• History of surgery except or gastrointestinal disease which might significantly change absorption of medicines
• History of clinically significant allergies, including imatinib
• Clinical laboratory test values are outside the accepted normal range

• AST(ASpartate Transaminase), ALT(ALanine Transaminase)( > 1.5 times to normal range
• Estimated GFR(Glomerular Filtration Rate) < 80 mL/min
• History of caffeine, alcohol, smoking abuse

• caffeine > 4 cups/day
• grapefruit juice > 4 cups/day
• smoking > 20 cigarettes/day
• alcohol > 140g/week
• Participated in a previous clinical trial within 3 months prior to dosing
• Donated blood within 60 days prior to dosing
• Use of prescription only medicine and oriental medicine within the 14 days before dosing or use of non-prescription medicine within the 10 days before dosing
• Subjects considered as unsuitable based on medical judgement by investigators